For human health, leishmaniasis is among the most important protozoan diseases, superseded only by malaria. Globally, 10 to 12 million people are infected with 1.5 million new cases every year. The development of cheaper new drugs is urgently needed for this neglected disease that is developing resistance to current treatments. Chemotherapy remains the only treatment option for the bulk of patients. However, this is largely unaffordable for most. In the past three years numerous advances in drug discovery have been made for treating this disease by exploiting diverging metabolic pathways between the Leishmania enzymes and their hosts, using nanotechnology to target the immune cell phagolysosomes where Leishmania resides.
Drug Discovery for Leishmaniasis aims to provide a perspective of the current treatments and their challenges, blended with the emerging strategies and methodologies that will drive new target appraisals and drug developments, as well as addressing the molecular basis of resistance in Leishmania.
Recent studies have shown that leishmaniasis affects some of the poorest people in the world, with 95% of fatal cases occurring in only 6 countries. With the WHO goal of eliminating this public health problem in the South-east Asia Region by 2020, this book will be important for anyone who is interested in neglected tropical diseases.
Dr Luis Rivas currently belongs to the scientific staff of the Center for Biological Research (Madrid, Spain) inside the Spanish National Council for Scientific Research Organization (Consejo Superior de Investigaciones Científicas, CSIC). He earned his PhD in Biochemistry (University Complutense of Madrid, 1984). After completing his PhD, he moved to the Weizmann Institute of Science, (Rehovot, Israel) and to Yale University (CT, USA) to complete his formation as a postdoctoral fellow. He focused on the design of antimicrobial peptides and on cell penetrating peptides as new drugs and vehicles for Leishmania chemotherapy. Another line is the elucidation of the mode of action of drugs targeting the bioenergetic mechanism of the parasite. He published 80 publications in referred international journals, mostly addressing Leishmania chemotherapy and molecular basis of peptide-pathogen interaction.
Dr Carmen Gil is staff scientist at Center for Biological Research of Spanish National Council for Research (CSIC) with a background in Medicinal Chemistry and Pharmacy. She received her Ph.D. from Complutense University of Madrid in 2001. After a postdoctoral appointment at Bonn University (Germany) she joined the CSIC. Her research is oriented to the discovery and development of new small-molecules as innovative target-based drugs and her research areas have been focused on phosphodiesterase and kinase inhibitors as innovative drug candidates for neurodegenerative diseases. She is involved in different projects that apply her background and experience in the development of specific parasite phosphodiesterase and kinase inhibitors in the fight for neglected parasitic diseases. She is author of more than sixty scientific publications, has four active patents in the field and has contributed to several books.
